Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drastic action by Schultz aims to right Teva’s ship

Executive Summary

Teva president and chief executive Kåre Schultz is seeking to achieve cost savings of US$3 billion by the end of 2019, through significant cuts to the firm’s staff, facilities and product portfolio. David Wallace reports.

You may also be interested in...



Five Things Facing Teva’s New CEO Richard Francis

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.

Countries To Discuss Pandemic Treaty Next Year Amid Industry Concern

A World Health Organization negotiating body has agreed to develop a “zero draft” of the proposed pandemic treaty for discussion at a meeting of WHO member states in February next year. But the international pharmaceutical industry has reiterated its concerns about some of the proposals being put forward.

To Prevent Shortages, US FDA Wants Sponsor To Provide Notifications Of Demand Spike

Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB000164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel